الفهرس 
List of contentsOnly 14 pages are availabe for public view
 |  | from | 102 |  |  |
| | | from | 102 | | |
Abstract
PET-CT with 18F-FDG has a great impact on the diagnosis and treatment of oncological diseases. 18F-FDG is more uptaken in cancer cells than in healthy cells. In clinical routine, SUV is often used to determine the glucose metabolism in tumors by 18F-FDG PET/CT. And can be further normalized to SUVs in reference regions resulting in an SUV ratio. In routine work SUV of the lesion is normalized to SUV of the liver, but this is not used if the liver is diseased like as liver cirrhosis or liver metastases. We aimed to assess the validity of the MBP SUV ratio in tumor differentiation in comparison to the liver SUV ratio in correlation to pathology and to determine the effect of age, sex, weight, BGL, and uptake period on liver and MBP SUV and assess variability of FDG uptake between different tumor types. This study included 151 patients who underwent initial PET/CT scans in the nuclear medicine unit at Assiut University Hospital before receiving any treatment. We found that the SUVmax/MBP ratio is valid for tumor differentiation but the SUVmean/MBP ratio and SUVpeak/MBP ratio are not valid for tumor differentiation.